跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 11,168 条关于
“ALK+ NSCLC”
全部
11,168
临床试验
8,507
药物
514
机构
78
资讯
2,069
6个月前
TRIANA Biomedicines' TRI-611 Receives FDA Fast Track Designation for ALK+ NSCLC Treatment
去年
Patient-Caregiver Preferences Study Reveals Key Treatment Decision Factors in ALK+ NSCLC
去年
Ongoing Trials Explore Novel Combinations and Adjuvant Therapies in EGFR- and ALK-Mutant NSCLC
去年
Adjuvant Alectinib Confirmed as New Standard of Care in ALK+ NSCLC with Favorable Safety Profile
5年前
Lorlatinib Shows Promising Efficacy in ALK-Rearranged NSCLC with 21.8 Month Median PFS
去年
ALNEO Trial Demonstrates Promising Perioperative Alectinib Activity in Stage III ALK-Positive NSCLC
去年
Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC
去年
Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC
去年
Adjuvant Crizotinib Fails to Improve Disease-Free Survival in Early-Stage ALK-Positive NSCLC
去年
Five-Year CROWN Trial Data Establishes Lorlatinib as First-line Standard for ALK+ NSCLC
第 1 页,共 207 页
上一页
下一页